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Abstract
Polycystic Ovarian Syndrome (PCOS) is multi-organ syndrome that affects 
6–25% of females during reproductive age. It disrupts normal hormone levels 
of females and affects adrenal hormone and sex hormones along with pituitary 
hormones including adrenocorticotropic, growth hormone and gonadotropins 
hormones. It results in several secondary characteristics in females such as infertil-
ity, hormonal imbalance, oligomenorrhea, amenorrhea, obesity and hirsutism. 
Polycystic ovarian syndrome is associated with mental and reproductive disorder 
and almost 4–18% mature female students are affected by polycystic ovarian 
syndrome. Female affected by polycystic ovarian syndrome have increased risk 
of infertility, ovarian cancer, skin problems and psychological problems such as 
anxiety, depression and changes in sleep along with mood swings. This chapter 
discusses the Prevalence, Symptomatology and Management of Polycystic Ovarian 
Syndrome. For the management of PCOS, the role of some medicinal plants includ-
ing Asparagus racemosus, Tinospora cordifolia, Foeniculum vulgare, Ocimum tenuiflo-
rum, Actaea racemosa, and Lepidium meyenii have also been discussed in addition to 
other treatment modalities. The literature data was searched out and compiled using 
relevant original research articles and reviews published and indexed in Google 
Scholar, Scientific Information Database, Elsevier, PubMed and Science Direct.
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1. Introduction
Polycystic Ovarian Syndrome (PCOS) is a multi-organ syndrome that disturbs 
the normal hormone levels of females and affects the sex and adrenal hormones as 
well as pituitary hormones including growth hormone, adrenocorticotropic hor-
mone and gonadotropins [1]. Female illness PCOS commonly results in hormonal 
imbalance, infertility, amenorrhea, oligomenorrhea, hirsutism and obesity. This 
study will contribute to the knowledge of prevalence, awareness, practices and 
attitudes of female university students towards polycystic ovarian syndrome and 
will enables us to understand the new approaches to control this issue for further 
strengthening as well as precautions and better treatment methods.
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The most common female syndrome is known as PCOS. PCOS is a state of 
illness that mostly disturbs the hormonal levels in women [1]. Polycystic ovarian 
syndrome can affect the pituitary hormones including growth hormone, gonado-
tropin hormone, adrenocorticotropic hormone (ACTH) and can also affect the 
adrenal and sex hormones, that’s why this syndrome can be called as multi organ 
syndrome [2].
The female reproductive organs consist of gonads known as the ovaries. The 
function of ovaries is to release mature and properly developed ovum and increase 
the secretion of steroid hormones. Pituitary gland secretes hormones LH and FSH 
which are controlling the functions of ovaries [3].
To diagnose PCOS, recently introduced criteria called Rotterdam Criteria is 
being practiced. According to this criterion, the diagnosis of PCOS depends upon 
the presence of hyperandrogenemia, oligo-ovulation and presence of inflamed 
ovaries on ultrasonography. Polycystic ovarian syndrome is classified as a set II 
ovulation sickness according to World Health Organization (WHO). About 4 to 18 
percent women of child bearing age are suffering from polycystic ovarian syn-
drome. It is associated with metabolic, psychological and reproductive dysfunctions 
[4]. Those women that are suffering from polycystic ovarian syndrome are at risk of 
endometrial hyperplasia or cancer, infertility, obstructive sleep apnoea or inability 
to sleep, abnormal glucose metabolism, anxiety and depression [5].
The exact cause of polycystic ovarian syndrome is not known. Different studies 
demonstrate that there are some inborn abnormalities like follicular development 
and ovarian steroidogenesis which are important in the inflamed ovaries disorder. 
This syndrome is also associated with an excess of luteinizing hormone (LH), 
decreased secretion of follicle stimulating hormone (FSH) and continuous increase 
in gonadotropin-releasing hormone (GnRH) which contribute to ovulatory dys-
function and overproduction of androgen hormones [5].
A transmutation in polycystic ovarian syndrome proteins also correlates with 
multiple environmental factors and inherited factors. There are multiple genes 
which are responsible for the incidence of polycystic ovaries disorder [6]. Most 
common endocrine complaint in female is PCOS. PCO has highly variable incidence 
such as 2.2 to 26% [7, 8]. The indications of polycystic ovarian syndrome may occur 
in adolescence. But it mostly diagnosed in adulthood. It is thought that differ-
ent life style and genetic factors take part in the occurrence of PCOS. It has been 
hypothesized that the earlier predisposing gestational factors of polycystic ovarian 
syndrome constitute the disturbed foetal programming in the uterus and birth 
weight [9].
Premature adrenarche has 15 to 20% risk of developing polycystic ovarian syn-
drome [10]. There was genetic predisposition in a female to developing polycystic 
ovarian syndrome [11, 12]. Alteration in the life style including high caloric diet and 
reduced exercise ultimately leads toward insulin resistance and obesity which has 
been considered as aggravating factors for polycystic ovarian syndrome [13].
It has been found that there is an association between polycystic ovarian 
syndromes and stress. But in other studies, stress is not considered as a causative 
factor of polycystic ovarian syndrome. The rate of incidence of polycystic ovar-
ian syndrome depends upon the criteria used to define this disorder. In 1980s the 
ultrasound imaging showed that inflamed ovaries were mostly associated with 
hyperandrogenemia and hirsutism in the females with continuous ovulatory cycle 
[14, 15]. It was also revealed in different studies, that there are some similar share of 
biochemical features in female with PCOS and regular rotations [16].
The incidence of premenstrual syndrome appears to vary in different countries. 
In the U.S., according to NIH criteria two studies have showed 4% prevalence rate 
in a 400 population [17]. About 6.6% prevalence rate have been documented in 
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females of south-eastern university [18]. From other races the incidence among 
females seems to be similar. The similar incidence rates of 6.5% also found in a study 
on 154 Caucasian females in Madrid, Spain [19].
Thus, the incidence of clinically evident PCOS in childbearing female in 
America and Europe ranges from 6.5 to 8.0% if the 1990 NIH criteria are applied. 
The incidence raises about two to three folds if the Rotterdam criteria are applied. 
The prevalence of polycystic ovarian syndrome seems to be lower in Asian countries 
with a reported incidence rate of 2.4% in China [20]. The prevalence rate reported 
in Sri Lanka is 6.3% according to Rotterdam criteria [21].
Common endocrine system sickness that affects women of childbearing age is 
known as PCOS And can also be mentioned as Stein-Leventhal syndrome or hyper 
androgenic involution (HA). In 1935 Stein and Leventhal described that polycystic 
ovarian syndrome represents a state in which approximately 10 cysts are made on 
ovaries and have diameter 2 to 9 mm. The ovarian volume exceeds about 10 ml in at 
least one ovary [22].
Almost, 7 million females in U.S. have been affected with polycystic ovarian 
syndrome from which more than half females are aware about polycystic ovarian 
syndrome and remaining are unaware about PCOS. Polycystic ovarian syndrome 
awareness not only concern to treat a disease in spite of it, PCOS concern is to 
improve the female health and make easier their living style [23].
Polycystic ovarian syndrome is associated with mental and reproductive disor-
der and almost 4–18% mature female students are affected by polycystic ovarian 
syndrome [24]. Females effected by polycystic ovarian syndrome have increased 
risk of infertility, ovarian cancer, skin problems and psychological problems such 
as anxiety, depression and changes in sleep along with mood swings. Polycystic 
ovarian syndrome is still unknown aetiology but in several studies it is assumed that 
polycystic ovarian syndrome is inherited and also associated with follicle stimulat-
ing hormone (FSH) and luteinizing hormone (LH). Excessive secretion of LH and 
decreased formation of FSH lead to excessive release of gonadotropin hormone, 
which causes ovulatory disturbance [25].
Polycystic ovarian syndrome has various symptoms such as weight gain, acne, 
excessive hair growth on unwanted body parts, irregular menses, and psychological 
problems like anxiety, depression, sleep & voice changes, and also include dys-
menorrhea. Hirsutism is defined as excessive hair growth on unwanted parts of the 
body in 10% of females caused by excessive production of male hormone androgen 
which is significantly associated with polycystic ovarian syndrome. Amenorrhea 
is defined as the lack of menstrual cycle in female of reproductive age, it can be 
primary (due to hormonal imbalance) and secondary (absence of menstrual cycle 
for more than 6 month) [26].
Major complications of polycystic ovarian syndrome are hypertension, diabetes 
mellitus, obesity, cardiovascular disorder, ovarian cancer, skin problems, liver 
diseases and psychological disorders [27]. The combination of hirsutism, infertility, 
oligomenorrhea and two sided enlargement of polycystic ovaries was recognized 
as reported in an article by Stein and Leventhal in 1935 [28]. Syndrome for some 
time period was known by their name. The term PCOS seem to be looked in 1960s 
and progressively substituted by the name of Stein-Leventhal syndrome. A major 
histopathological study conducted in 1982 [29] revealed a comprehensive detail 
about ovaries, which are inflamed and contain large number of small fluid filled 
cysts of 10 mm diameter.
The sac of the ovary may be similar with a bulge, so the presence of cystic 
imaging in the ovary must be deliberated as a normal event. It is only the excessive 
number of ovarian follicle that necessarily be considered as a disease condition 
associated by means of polycystic ovarian syndrome. Consequently it is correct 
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and precise to state ovaries containing large number of follicle instead of polycysts. 
After Initiation of ultrasound, the follicular surplus became the main feature in the 
morphology of polycystic ovaries.
An increase in ovarian area (OA) and ovarian volume (OV) are being considered 
as the exact and accurate markers of polycystic ovarian morphology (PCOM). 
These two markers provided the dimensions that are voted for the middle segment 
of the berries. It is confirmed from histopathological studies that both ovarian area 
(OA) and ovarian volume (OV) are infect good indications of follicular excess and 
stromal hypertrophy which are the structural or anatomical symbols of the polycys-
tic ovarian morphology (PCOM) [30].
The most common cause of menstrual disruption such as anovulation, infertility, 
oligo menorrhea and menorrhagia, is the polycystic ovarian syndrome [31]. In the USA, 
Spain and Greece, the incidence of polycystic ovarian syndrome was assessed to be 4 to 
8%. The prevalence of polycystic ovarian syndrome is increasing all over the world and 
is presenting great increase in parallel with type 2 diabetes mellitus (T2DM) [32].
There were about 116 million females affected by polycystic ovarian syndrome 
in all over the world. In 2009, about 5 to 10% women were affected by polycystic 
ovarian syndrome in Pakistan [33]. Polycystic ovarian syndrome is heterogeneous 
disorder that is associated with polycystic ovarian morphology, hyperandrogenism 
and ovulatory dysfunction regarding to the pathophysiology. It’s distinctive neu-
roendocrine feature include increased ratio of luteinizing hormone and follicular 
stimulating hormone (LH/FSH), increased serum level of luteinizing hormone 
(LH) and increased frequency and rate of LH secretion [34].
Gonadotropin releasing hormone (GnRH) secreted from hypothalamus binds to 
its receptors that are present on secretory cells of adenohypophysis. Gonadotrophs 
create LH and FSH in reply to GnRH, and these two hormones (LH, FSH) regulate 
reproductive processes in the body and regulate the pubertal growth, maturation 
and development [35]. Follicular stimulating hormone and luteinizing hormone 
stimulate the ovaries to produce oestrogen hormone in females and inhibit to regu-
late the menstrual cycle. By inhibiting the production of gonadotropin releasing 
hormone (GnRH), oestrogen forms a loop of negative feedback mechanism [36].
In polycystic ovarian syndrome, the level of progesterone hormone is decreased 
which cannot reduce the frequency of GnRH/LH pulse. Hence, the increased secre-
tion of oestrogen hormone may lead towards the formation of autoantibodies in the 
body. Recently, there are two commonly recognised investigative criteria of poly-
cystic ovarian syndrome and both suggest the presence of two out of three signs to 
be characterized as polycystic ovarian syndrome (PCOS) [37].
Obesity aggravates different types of comorbidities of polycystic ovarian syn-
drome for example diabetes, heart disease, hypertension (HYN) and hypercholes-
terolemia. An ovulation in polycystic ovarian syndrome leads towards unrestricted 
oestrogen secretion which is a risk factor for carcinoma and endometrial hyperpla-
sia. Quality of life reduces by depression, obesity, hirsutism and infertility caused 
by polycystic ovarian syndrome (PCOS). Kerchner et al. identified the depression 
in 40% of females of polycystic ovarian syndrome (PCOS). The incidence rate of 
suicide is increased by seven folds in polycystic ovarian syndrome [38].
In polycystic ovarian syndrome, there is an excessive production of oestrogen 
hormone which has been related to different types of autoimmune diseases. 
Oestrogen hormone increases the production of different interleukins like IL-1, 
IL-6, IL-4 and interferon-y. In polycystic ovarian syndrome, the level of progester-
one hormone is decreased and it triggers the immune system that ultimately leads 
towards the production of autoantibodies. Therefore, polycystic ovarian syndrome 
can be characterized as an autoimmune disorder [39].
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Females with PCOS had high risk to develop endometrial cancer while their 
risks of developing ovarian and breast cancer are same to those of females in overall 
common population. There are some health significances of polycystic ovarian 
syndrome including overweight, null parity and continued unrestrained increase 
of oestrogen that are highly liked with cancer. A study conducted by Barry found an 
important increase of about three folds for endometrial cancer among females hav-
ing polycystic ovarian syndrome. But there is no prominent increase in risk factor 
of ovarian or breast cancer [40].
Women of polycystic ovarian syndrome (PCOS) have a common feature of 
infertility. In general, infertility is considered as an ovulatory complaint. These 
types of patients are mostly treated with conservative therapies such as ovulation-
induction medications. These medications include clomiphene citrate (CC) or 
gonadotropins, and considered as first line treatment. These medications increase 
the incidence of multiple pregnancies. Due to the use of gonadotropins there is an 
excessive risk of ovarian hyper stimulation syndrome. These types of drug modali-
ties increase the risk of formation of different types of ovarian cysts, pain in ovaries 
and torsion of ovaries. For pregnancy and infertility problems, most commonly 
used drug is known as metformin [41].
A heterogeneous condition which has different phenotypic expression is known 
as polycystic ovarian syndrome (PCOS). Due to its phenotypic forms it becomes 
a controversial issue which is based upon the diagnostic criteria. The incidence 
of polycystic ovarian syndrome is about 6 to 15% and it depends upon the use 
of diagnostic criteria. Every patient experience the severity of the components of 
polycystic ovarian syndrome and its management is based upon the preferences of 
the patient. The most prominent endocrinopathy in females is known as polycystic 
ovarian syndrome (PCOS) with the incidence rate of 6.5 to 6.7% among those 
women who are in menopausal stage [42].
In 1990, this disorder was well known as the combination of biological and 
clinical increase in androgen hormones, chronic anovulation and oligomenorrhoea 
as presented in the NIH conference. The investigative criteria revised in 2003 by 
Rotterdam consensus [43], with the presence of either two or three following pre-
conditions including clinical chronic anovulation or oligomenorrhoea. Various pos-
sible pathophysiological consequences of polycystic ovarian morphology (PCOS), 
detected in 75% of females of polycystic ovarian syndrome (PCOS), has been 
comprehensively discussed. Further, it has been discussed that there is no associa-
tion between the metabolic irregularities of the typical polycystic ovarian syndrome 
phenotypes and the phenotype of anovulation combined with the morphology of 
polycystic ovaries [44].
2. Prevalence
Due to increase in endometrial and follicular activity level almost 100% 
polycystic ovarian syndrome patient suffered from amenorrhea, anovulation and 
infertility, its occurrence is also due to irregularity in their cyclic menstrual cycle. 
Almost 60% women’s had menstrual problems (amenorrhea, anovulation, infre-
quent bleeding) in a study conducted on 400 women of general population [45].
Sanchez et al. assessed the frequency of this syndrome in females in US (age 
18–45 years) is almost 6.6%. According to present study on polycystic ovarian 
syndrome, occurrence of PCOS is 6% because 6% were diagnosed as having PCOS 
while 16% girls were refer to doctor and 9% girls did ultrasonography and blood 
reports [46].
Alternative Medicine - Update
6
Joshi et al. reported that the prevalence of PCOS was extremely inconstant 
worldwide; fluctuating from 2.2–26%. They found 22.5% prevalence of PCOS by 
Rotterdam and 10.7% according to Androgen Excess Society criteria [47].
Joshi B and her group evaluated that PCOS is an evolving illness during puberty 
and screening to avoid illnesses and psychological problems [48]. Shetty D assess 
that around 10% Indian women was having PCOS symptoms like excessive hair 
growth in unwanted parts of the body, obesity and acne [49]. Choudhary et al. 
assessed 9.13% occurrence of PCOS in Indian youths [50]. Vaidya R considered that 
according to WHO, there was 116 million women throughout world were affected 
with PCOS in 2012 [51]. Lakshmi KS reported 32% occurrence of PCOS at a tertiary 
care hospital [52].
Radha P assessed that Indian woman had high risk of PCOS compared to their 
others counterparts, with an expected incidence of 9.13% in Indian youths [53]. 
Radha P assessed that 20% of contributors were diagnosed with PCOS. The per-
centage of PCOS was found increased in city area as compared to rural areas, due 
to their unhealthy life style [54]. Almost 9.5% girls consulted dermatologist for 
excessive hair growth on abnormal body parts or acne (major sign of PCOS), 4.5% 
female referred to gynaecologist for abnormality of periods, and 1% girls used 
herbal treatment while 1% used homeopathy.
Sills ES assessed that regardless of age, physicians are the most common pro-
vider of PCOS information for all (rather than other sources like paper, family and 
books) [55].
A research about the occurrence of PCOS was conducted at Taibah University Al 
Madinah Al Munawara on adult unmarried female students, aged 18–28 years. From 
201 contributors, 108 (53.7%) were diagnosed to have disorder with a mean age of 
21.3 ± 2.1 years, the demographic facts, menstrual irregularities and acne seen in 
108 students [56].
Polycystic ovarian syndrome is disturbing 5–10% population because it can 
cause infertility and endocrine diseases in women’s of child bearing age. Symptoms 
of polycystic ovarian syndrome usually arise during adolescence at the start of men-
struation and disturbed the females health and mental state, symptoms can be mild 
or severe. PCOS is a common endocrinology sickness in young females. Occurrence 
of PCOS in child bearing age women is 7 to 10% [57]. Study on the prevalence of 
polycystic ovarian syndrome was conducted in Karachi, Pakistan, to assess the ratio 
of affected females in Pakistan especially in Karachi [58].
In 2011 a study conducted in Rawalpindi to assess the prevalence of PCOS [43]. 
In India studies related to occurrence of PCOS was conducted at Thandalam, all 
these studies indicated that prevalence of polycystic ovarian syndrome is increas-
ing with time and most of our females are affected by PCOS [59]. A study was 
conducted in Karachi to evaluate the information and awareness of PCOS in urban 
Pakistani women at 2014 [60].
In present studies maximum adolescent and young girls (almost 33%) got 
knowledge about polycystic ovarian syndrome from teachers, 19% girls got knowl-
edge from friends, 11.5% females are diagnosed and informed by doctor, 3.5% 
female got knowledge by reading newspaper and 5% got knowledge from internet 
resources. Almost 28% young and adolescent girls are unaware about polycystic 
ovarian syndrome and 72% females have knowledge about polycystic ovarian 
syndrome symptoms, prevalence and severity.
According to Sunanda B et al. 76% females had average knowledge about poly-
cystic ovarian syndrome and 10.7% females had good information related to PCOS 
[61]. Sills ES assessed more than 97% females were aware with PCOS, while 1.9% 
had not been aware about PCOS, and < 1% females were unclear [62].
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3. Pathophysiology and aetiology of PCOS
The exact cause of polycystic ovarian syndrome is still unknown. PCOS is 
possibly a mixture of factors such as inheritances, ecological factors as well as 
fetal contact to high androgen in uterus. The polycystic ovarian syndrome has 
been noted a familial disorder which runs in families. Those who have PCOS 
positive family history in mothers or sisters have greater chances to develop the 
syndrome [63].
The current studies showed that polycystic ovarian syndrome run in families but 
it is not sex chromosomes disorder, it is of autosomal dominant pattern. A number 
of factors of polycystic ovarian syndrome have been known, that are associated 
with PCOS. Maternal causes include low or high birth weight in girls borne from 
obese females [64].
There are various risk factors like acanthus’s Nigerians (skin disorder), meta-
bolic, precocious puberty (puberty in the age of 7 to 9 years) and pubarche [65]. 
Weight gain sometimes leads toward the development of syndrome. PCOS is diag-
nosed in adolescent due to their irregular menstrual cycles. Maximum researchers 
evaluated those natural defects in steroid formation in ovaries and development of 
follicle play an important role in the etiology of PCOS. The syndrome is also related 
with insistently quick pulses of GnRH, an excessive production of LH, and inad-
equate production of FSH, which plays role in extreme ovarian androgen formation 
and loss of ovulatory function [66].
There are multiple familial genes which are responsible for the development 
of polycystic ovarian syndrome, many environmental as well as inherited factors 
which are the main cause in the mutation of polycystic ovarian syndrome protein. 
The result of transformation and scientific ascertainment reveals in everyday life 
and it completely altered our lifestyle. Consumption of diet is concentrated increas-
ingly on sugar, fast food, and soft juices and decrease from fresh vegetables and 
balanced diet. This unhealthy eating behaviors and lack of workout leads toward 
polycystic ovarian syndrome (PCOS) as well [67].
Causes of many symptoms are treated or become less dangerous because hor-
monal level become normal due to weight loss. Weight gain can be treated through 
exercise and balanced food.in last few years 30% Polycystic Ovaries Syndrome cases 
rise in India. This may occur due to unhealthy life style and lack of information 
about PCOS [68].
3.1 Pathophysiology
In the women of polycystic ovarian syndrome the gonadotropin releasing 
hormone (GnRH) level is increases or decreases in frequency with time. Due to 
decreased gonadotropin releasing hormone level, production of LH is increased 
resulting in decreased formation of FSH.
Increased level of luteinizing hormone stimulates the theca cells of ovaries to 
release androgenic hormone and may also disturb the menstruation. Moreover, this 
low level of follicle stimulating hormone cannot stimulate the granulosa cells of 
ovaries to convert androgen to estrogen, and ovulation cannot occur in the absence 
of estrogen.
Normally after ovulation, corpus lutein releases the progesterone hormone. 
Due to increase in progesterone level, the gonadotropin hormone level is decreased 
through feedback mechanism. Some readings have explored the role of the control-
ling genes of cytochrome P450 (CYP) 11A, FST, IVSR, 3-HSDL and CYP 17 enzyme 
in connection with PCOS.
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In the ovaries of PCOS theca cells changed whose cytochrome P450 (CYP) 
11A, 3- HSDL and CYP 17 gene display raised intensities. And there is practical 
anomaly of the 17 -hydroxylase which control androgen biosynthesis. Hereditary 
studies revealed a link among PCOS and hyper-insulinaemia. Insulin resistance at 
the margin and to irregular pancreatic 2 cell function is secondary to hyper-insu-
linaemia. 50–70% of females effected with PCOS due to insulin conflict. Increased 
insulin levels may affects the gonadotropin which acts on ovarian function. 
Ovarian function can be regulated with insulin, and excessive insulin stimulates 
the ovaries to produce gonadotropin. Increased insulin also subdue generation 
of sex hormone binding globulin (a carrier protein) which as a result increases 
androgenicity [69].
A scientific hallmark of PCOS is hyperandogenism, causing reserve develop-
ment of sac, micro cyst materialization in ovaries and anovulation [70]. Increase 
level of androgen and insulin affect menstruation and prevent ovulation.
3.2 Mechanisms of anovulation
There is prominent difference between follicle development as well as steroid 
genesis. One thinkable justification for this puzzle may be a marvel that is assumed 
to happen usually at the onset of the mid cycle of luteinizing hormone release. 
This syndrome is considered through excessive secretion of LH and insulin. 
Many patients have normal blood concentrations of LH has raised serum insulin 
level [71].
Insulin cooperates with LH in increasing steroidogenesis by granulosa cells of 
ovaries. Elevated stimulant intensities of LH and its augmentation of action on fol-
licle by hyperinsulinemia had explanation of detention of follicle development and 
improvement of estradiol release [72].
The “control” granulosa cells were differentiated and follicle is released which 
is then activated at the onset of mid cycle of LH release by intracellular cAMP. 
Production of cAMP was affected by insulin; it assumed that insulin increases the 
LH production due to which LH receptors are increased on growing granulosa cells. 
Excessive secretion of androgens from ovaries can affect follicle growth. Within 
granulosa cells, androgens enlarge gonadotropin-induced cAMP release [73].
4. Clinical features
Polycystic ovarian syndromes has various symptoms such as weight gain, acne, 
excessive hair development on unwanted body parts, irregular menses, and psy-
chological problems like anxiety, depression and sleep and voice changes and also 
include dysmenorrhea.
Hirsutism is defined as excessive hair growth on unwanted parts of the body in 
10% of females caused by excessive production of male hormone androgen which is 
significantly associated with polycystic ovarian syndrome. Amenorrhea is defined 
as menstrual cycle is absent in female of reproductive age, it can be primary (due 
to hormonal imbalance) and secondary (absence of menstrual cycle for more than 
6 months). Major complications of polycystic ovarian syndrome are hypertension, 
diabetes mellitus, obesity, cardiovascular disorder, ovarian cancer, skin problems, 
liver diseases and psychological disorders [74].
The combination of hirsutism, infertility, oligo menorrhea and two sided 
enlargement of polycystic ovaries was recognized by Stein and Leventhal. For some 
time period, syndrome use their name. The word polycystic ovarian syndrome 
(PCOS) seems to be looked in the 1960s and progressively changed by label of 
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Stein-Leventhal syndrome. Last main histopathological study was conducted in 
1982 [75].
And it delivers a comprehensive explanation of the polycystic form of the 
ovaries and the number of follicles that are 10 mm in diameter. Cyst may resemble 
with ovarian follicle, so the existence of cyst within ovary must be deliberated as 
a usual experience. Extreme number of ovarian follicle that considered as disease 
ailment is associated by polycystic ovarian syndrome. Therefore it is correct and 
precise to express as ovaries containing large number of follicle instead of polycyss. 
A rise in ovarian area and increased volume was considered the exact and accurate 
markers of polycystic ovarian morphology (PCOM). These two markersprovided 
the dimension that was passed out on the middle segment of the ovaries.
It is confirmed from histopathological studies that both ovarian area (OA) and 
ovarian volume (OV) are infect good indications of follicular excess and stromal 
hypertrophy which are the structural or anatomical symbols of the polycystic ovar-
ian morphology (PCOM). Hyperandrogenism (Acne, hirsutism, alopecia); 60% 
PCOS females are suffered with hirsutisim on chin, face upper lips, buttocks [76].
Irregular menstrual cycle means cycle repeat much time within month or may 
absent for several months. Almost 85% - 90% of women of oligomenarrhoea have 
PCOS worldwide, while 30–40% of amenorrhea women also affected with this 
syndrome. Heavy or flimsy menstrual flow indicates polymenorrhea and oligo 
menorrhea. Lack of ovulation may lead toward infertility and subfertility/70% 
of pregnancy problem due to anovulation are connected to inflamed ovaries [77]. 
Fatness with BMI > 35 kg/m2.
Some other features are:
• Weakening and falling of hair.
• Membranes label below the armpits, neck and below knees.
• Temper complaints such as hirsuitism are common in teenage. Most of females 
often feel unsatisfied and depressed if they expected difficulty to loose weight, 
cure acne, abnormal body hair and menstrual problems.
• Cardiac abnormalities.
• Pre diabetes and diabetes
• High total cholesterol and low good cholesterol and high LDL
• Almost 25% females with PCOS had elevated prolactin levels [78].
5. Diagnostic criteria of PCOS
European Society for Human Reproduction and Embryology/American Society 
for reproductive medicine – funded PCOS workshops in 2004. definition of this 
syndrome must include two out of the subsequent three conditions:
1. Absence of menstrual cycle for 6 months.
2. Medical or organic symbols of increase androgen product.
3. Inflamed ovaries on ultrasound.
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Polycystic ovary was redefined, ovary with more than 12 follicles of size 2–9 mm 
in diameter.
These standards are not proper for all females, because some PCOS girls had no 
cyst and experience regular periods.
• Insulin resistance is most common in all PCOS females. 70–95% obese and 
30–75% lean PCOS females are affected. This can lead to diabetes and cardio-
vascular disease in PCOS females.
• It also responsible to raised plasminogen activator inhibitor −1 (PAI-1) in 
patients with PCOS. Elevated PAI-1 can cause intravascular thrombosis.
• Endometrial hyperplasia and endometrial cancer are thinkable, due to over 
gathering of uterine lining, due to deficiency of progesterone hormone causing 
stimulation of uterine cells by oestrogen hormone.
• Breast cancer, obesity and infertility are common in PCOS patients [79].
PCOS mostly affect the obese female’s then lean built. Moreover pregnant 
women suffered with PCOS should be informed about miscarriage, gestational 
diabetes, pre-eclampsia, eclampsia and premature delivery. Barry found significant 
rise of three folds for endometrial cancer among females suffered with polycystic 
ovarian syndrome. But there is no prominent increase in it [80].
6. Investigations
To eradicate all other illnesses that may cause menstrual problems, breast cancer 
and infertility, the most common diagnostic tests include ultrasound, FNAC and 
reproductive hormones like estrogen and progesterone.
7. Management
The vital treatment option for polycystic ovarian syndrome is the lifestyle modi-
fications in those cases in which different risk factors are correlated to stimulate 
the presentations of polycystic ovarian syndrome (PCOS). Treatment modalities 
are included in other types of intermediations. The main objective of these types 
of modifications is to decrease the weight and maintain reduced body weight for 
longer time. Improvement of insulin resistance through weight loss with the help 
of exercise and diet seems to contribute to the development of metabolic, clinical, 
and hormonal factors of polycystic ovarian syndrome (PCOS). Though even the 
uncertain weight loss has been revealed to increase the incidence of ovulation, 
improvement of hormonal factors and decrease metabolic defects in the females 
affected with polycystic ovarian syndrome.
Life style modification is very essential in overweight patients. Every female 
with polycystic ovaries disease can take advantage from a proper balanced diet and 
consistent exercise. In most of programmes of dietary involvement, the energy 
restriction has been forefront while excellence of diet may also play a major role in 
polycystic ovarian syndrome.
To accomplish long term reduction in weight is the major difficulty in poly-
cystic ovarian syndrome. Additional medical therapies are also necessary. In the 
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management of PCOS, there was a stimulating pathophysiological background to 
sustain the therapeutic benefits of insulin sensitizers including hyperandrogen-
aemia, metabolic characteristics and ovulatory functions. Accessible literature deliv-
ers acceptance to this whole concept and inspires the addition of insulin sensitizers 
in the therapeutic management of polycystic ovarian syndrome. There are two main 
and most beneficial insulin sensitizers including metformin and thiazolineodiones.
Moreover, different traditional drugs such as clomiphene, oral contraceptives, 
and antiandrogens drugs are used in the management of polycystic ovarian syn-
drome. These medications have been considered as supplementation by original 
pharmacological modalities including insulin sensitizers. Lifestyle modification 
is still considered beneficial therapeutics. The most commonly studied insulin 
sensitizer is known as metformin due to its comforting safety profile.
Metformin aids to reduce visceral adiposity, weight loss and decrease insulin 
resistance commonly at the muscle and hepatic tissue level and it contribute to a 
more approving hormonal as well as metabolic profile. The metabolic actions of 
metformin are well recognised in other patients like obese and slim women present-
ing with PCOS. In a meta-analysis of different people, such as 13 controlled studies 
of females with polycystic ovarian syndrome it established that metformin has 
essential role to decrease fasting insulin levels [81].
PCOS is still unknown disorder and has no specific treatment. But it can be 
treated and managed in several ways. Regularity of menstrual cycle, improve skin 
disorders and reduce insulin and androgen level are the aims of management for 
young women. Initial treatment for women with PCOS is life style modification like:
1. Take protein, keep low carbohydrate.
2. Workout.
3. Loss weight.
4. Pharmacological treatments are used.
i. Overweight:
BMI > 30 kg/m2 considered as overweight and should be encouraged to 
loose weight.
ii. Menstrual abnormality:
Use low dose combined oral contraceptive to manage menstrual cycle.
iii. Metformin become common medicine selected for this population.
Spironolactone or Flutamide are androgen lowering medication, but shows their 
effect slowly. Metformin is an anti-diabetic drug that can be used to recover fertil-
ity, decline insulin conflict, regulate menses, and recover cardiovascular health in 
teenagers with PCOS. Aromatase inhibitors are suitable for females of clomiphene 
resistance. Some girls with PCOS develop depression, therefor they need mental 
health professional [82]. Cancerous cysts are removed surgically. Ovarian drilling 
is the best surgery to cure infertility. It is necessary for PCOS girls to consult their 
doctor often and use proper medication and precaution to regulate periods and 
decrease the chances to develop diabetes, CVS and skin issues.
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8. Medicinal plants
8.1 Asparagus racemosus (Shatavari)
In traditional ayruvedic medicine Asparagus racemosus (Asparagaceae) is used 
which aids in regulation of menstrual cycle, stimulating the normal growth of 
ovarian follicles and strengthening the female reproductive system mostly due to 
phytoestrogen (known as natural plant consisted of estrogen). It also helps in resist-
ing the hyperinsulinemia [83].
A. racemosus has many other pharmacological effects in addition to above, like 
tumors, inflammation, neuropathy, nervous disorders, dyspepsia, neuropathy, and 
hepatopathy. It also acts as antiulcer, antioxidant and anti-diarrheal. A. racemosus 
also helps in preventing aging, increase the endurance of life as well as improves 
mental function and immune modulatory activities [84].
8.2. Tinospora cordifolia (Guduchi)
Tinospora cordifolia, (Menispermaceae) is a well-recognized medicinal plant 
which has hypoglycemic effect [82]. It is a powerful and effective inflammatory 
herb. The basic cause of insulin imbalance and ovarian cysts is the chronic inflam-
mation in tissues. Tinospora Cordifolia aids in strengthening all the body tissues, 
increasing metabolism and lowing the insulin resistance [85].
8.3. Foeniculum vulgare (Shatapushpa)
The seeds of Foeniculum vulgare, (Apiaceae) are used as an excellent supplement 
for managing the polycystic ovarian syndrome (PCOS). Seeds are the richest source 
of phytoestrogsns. In fennel, these phytoestrogens helps in decreasing insulin 
resistance and in lowering the inflammation in PCOS. It is also thought that it helps 
in lowering the cellular imbalance which ultimately leads towards the metabolic 
disturbances in PCOS [86].
Currently, various parts of this medicinal plant are used in the management and 
treatment of many disorders, specifically digestive system disorders. Moreover, it 
is highly useful in the treatment of inflammation of bronchioles, chronic cough, 
diabetes mellitus, kidney stones as well as in nausea and vomiting [87].
8.4. Ocimum tenuiflorum (Holy Basil)
A traditional herbal medicine Ocimum tenuiflorum L. (Lamiaceae) generally known 
as Tulsi. Ocimum tenuiflorum is very effective for polycystic ovarian syndrome. It lowers 
the production of androgen because it has tremendous anti-androgenic properties [88].
8.5. Actaea racemosa (Black Cohosh)
In many disorders of female reproductive system like anvolution, hormonal 
imbalance, infertility, the Actaea racemosa (Ranunculanae) is used because these are 
important issues in PCOS. Black Cohosh has the capability to stimulate the ovula-
tion in females with PCOS [89].
8.6. Lepidium meyenii (Maca)
A traditional herbal medicine Lepidium meyenii from Brassicaceae family is used 
in treating the menopausal symptoms, stimulates the endocrine system. It acts as 
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natural hormonal balancer without any adverse effects. Progesterone and estrogen 
hormones help in encouraging the healthy menstrual cycle in the body. It is an 
implausible fertility super food as well as an adaptogen. Maca also restores the level 
of testosterone in males [90].
9. Conclusion
The incidence of polycystic ovarian syndrome is rising day by day but students 
were not aware and conscious of polycystic ovarian syndrome (PCOS) even though 
the different features regarding to this syndrome were present in many students. 
Therefore, few teaching projects or schemes have to be prepared to make available 
information related to these types of disorders in women. Moreover, survey shows 
many women do not discuss with gynaecologist until there is rigorous or difficult 
situation occurred. Consequently, women must have to talk to any gynaecologist or 
doctor for health and fitness. The last prominent matter was about the contempla-
tion of the society about polycystic ovarian syndrome. The most common answer 
suggested that the people needed awareness concerning the polycystic ovarian syn-
drome and also most people said that it is significant issue to be discussed because 
there were misconceptions about polycystic ovarian syndrome.
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